Compounded medicines in South Africa raise safety questions

A court case in South Africa has drawn public attention to a practice that most patients never think about: compounding, the preparation of medicines outside a licensed manufacturing facility, typically by a pharmacist, to meet an individual patient's needs.

Behind the legal proceedings, Professor Renier Coetzee and Lara van Niekerk argue that a deeper set of questions remains unresolved — specifically, whether South Africa's current systems are equipped to ensure these medicines are safe before they reach patients.

What compounding is, and why it matters

Compounded medicines are not mass-produced. They are prepared individually, often when a standard commercial product is unavailable, unsuitable for a particular patient, or needs to be reformulated — a different concentration, a liquid instead of a tablet, the removal of an allergen.

For people with albinism, this kind of tailored preparation can be directly relevant. Compounded sunscreen formulations, for instance, are sometimes prepared at higher SPF concentrations than those available off the shelf, or in bases that suit specific skin sensitivities. Access to such preparations depends, in part, on whether the compounding system is trusted and regulated.

The oversight gap

Pharmacovigilance — the monitoring of medicines for adverse effects once they are in use — is well established for commercially manufactured drugs. Coetzee and Van Niekerk argue, according to the AllAfrica report, that compounded medicines sit in a more uncertain space. Because they are prepared in smaller quantities, often for a single patient, they move through fewer checkpoints than factory-made equivalents.

The researchers contend that this is not a reason to restrict compounding, but a reason to strengthen the systems around it. Monitoring, reporting, and regulatory clarity are the tools they identify as most in need of attention.

South Africa's South African Health Products Regulatory Authority (SAHPRA) holds responsibility for medicines regulation in the country, but the specific frameworks governing compounded preparations have, according to the authors, lagged behind the growth of the practice.

Why this matters for the albinism community

For any community that relies on specialist or tailored medical products — including high-factor sun protection that standard retail does not always supply — the integrity of the compounding system is a practical concern, not an abstract one.

Coetzee and Van Niekerk's argument is not alarmist. It is, as they frame it, a call for proportionate oversight: systems that protect patients without making access harder.

The court case that prompted this discussion has not yet resolved the underlying regulatory questions. Those questions, the researchers suggest, will need legislative and institutional answers that outlast any single verdict.